EULAV Asset Management Sells 32,000 Shares of DexCom, Inc. (NASDAQ:DXCM)

EULAV Asset Management lessened its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 39.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 49,000 shares of the medical device company’s stock after selling 32,000 shares during the period. EULAV Asset Management’s holdings in DexCom were worth $3,811,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Sumitomo Mitsui DS Asset Management Company Ltd increased its position in shares of DexCom by 15.4% in the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 47,263 shares of the medical device company’s stock worth $3,676,000 after purchasing an additional 6,290 shares during the period. Consolidated Portfolio Review Corp acquired a new position in shares of DexCom in the 4th quarter valued at approximately $220,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of DexCom by 13.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 147,911 shares of the medical device company’s stock worth $11,768,000 after acquiring an additional 17,650 shares during the period. Stratos Wealth Partners LTD. acquired a new stake in shares of DexCom during the 4th quarter worth approximately $201,000. Finally, E. Ohman J or Asset Management AB boosted its position in shares of DexCom by 12.1% during the 4th quarter. E. Ohman J or Asset Management AB now owns 17,600 shares of the medical device company’s stock worth $1,369,000 after acquiring an additional 1,900 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, EVP Jereme M. Sylvain sold 2,090 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the sale, the executive vice president now owns 83,526 shares in the company, valued at $7,259,244.66. The trade was a 2.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the transaction, the chief operating officer now owns 268,644 shares in the company, valued at approximately $23,347,850.04. This represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 42,342 shares of company stock worth $3,628,069. Company insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

DXCM has been the subject of several recent analyst reports. Citigroup upped their target price on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and raised their price objective for the company from $85.00 to $115.00 in a research note on Monday, February 3rd. Sanford C. Bernstein raised their price target on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. Leerink Partners lowered their price objective on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Finally, Canaccord Genuity Group increased their price objective on shares of DexCom from $89.00 to $99.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Four analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $98.41.

DexCom Trading Down 0.3 %

DXCM opened at $88.08 on Friday. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The company has a fifty day moving average of $81.56 and a 200-day moving average of $75.78. The stock has a market cap of $34.40 billion, a PE ratio of 52.74, a price-to-earnings-growth ratio of 2.23 and a beta of 1.14. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.